Written Question · S1W-11601 · Session 1
What plans it has to address the situation where 2% of MS sufferers receive Beta Interferon compared with over 10% in Europe and a greater …
The question
To ask the Scottish Executive what plans it has to address the situation where 2% of MS sufferers receive Beta Interferon compared with over 10% in Europe and a greater percentage in Australia.
The answer
The Health Technology Board for Scotland have agreed to my request that they provide advice on the clinical and cost-effectiveness of the use of Beta Interferon and Copaxone in the treatment of multiple sclerosis. This authoritative evidence-based advice will help to address variation in the use of this treatment across Scotland by defining national standards for its use.
In the Official Report
No contribution in the Official Report cites S1W-11601 by reference.